Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that their work should heal and repair the wounds of racial difference as ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursive / Stack → climbing stairs with a backpack (stack grows with height). Morris Traversal → climbing stairs using only your hands on rails (no extra backpack). Threaded Tree → installing ...

Abstract: Neural combinatorial optimization methods have addressed many routing problems effectively, but the capacitated arc routing problem (CARP) poses a significant challenge due to its ...

A routine has been developed which computes and prints out the symbolic derivative of an absolutely continuous elementary function of one or several variables. No use is made of list processing ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...

As attackers continue to evolve, Microsoft is committed to staying ahead by not only responding to vulnerabilities, but also by anticipating and mitigating entire classes of threats. One such threat, ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.

Traversal Inc., a startup building an artificial intelligence platform focused on site reliability engineering and observability, today announced its launch with $48 million in funding. The funds were ...